Clinical Trials

Cardioxyl previously completed a Phase IIa dose-defining study to evaluate the hemodynamic effects, safety and tolerability of CXL-1020, its initial nitroxyl (HNO) donor clinical candidate, in patients with acute decompensated heart failure (NCT01096043). Prior to that study, the company concluded a Phase I/IIa Dose-Escalation Study evaluating the safety and tolerability of CXL-1020 and specific effects on electrocardiographic and non-invasive hemodynamic parameters in patients with chronic heart failure (NCT01092325). More information is available on ClinicalTrials.gov. Having demonstrated human proof of concept with its first-generation compound, Cardioxyl has now advanced its improved second-generation HNO donor, CXL-1427, into the clinic. The first Phase I trial with CXL-1427 was initiated in February 2014.

Nitroxyl Technology

Cardioxyl has developed proprietary expertise in the biology, physiology and chemistry of nitroxyl donors

View More

Our Mission

Cardioxyl's mission is to realize the potential of nitroxyl technology through the development of novel therapies that improve the health and quality of life of patients with serious cardiovascular disease.